Carevature Medical: Harnessing Technology to Improve Spine Care

- **Investment Rational**
  Degenerative Spine surgeries present low success rates thus call for innovation; advanced technologies like navigation and robotics were so far aiming to improve only a limited part of the procedure while the source of the problem remains treated in traditional ways. Carevature identified the need in modernizing the current procedures for improving care and economics of this field.

- **Business Strategy**
  Carevature presents ongoing revenues from its FDA, CE-cleared Dreal® legacy line of freehand devices for spinal decompression, in parallel to the development of the next-generation, first-of-its-kind, surgeon-controlled and vision-guided "cobot" for spine surgery. The robotic platform is designed to match the most recent trends in the field, namely minimally-invasive procedures and the shift to treatments in outpatient facilities.

- **Core Technology**
  Carevature originally developed a technology for precise tissue removal in hard-to-reach anatomies, which is valuable in spinal decompression for removing pathological bone, while preserving the surrounding tissues critical to healing and functioning of the spine. The patented technology was implemented in a suite of devices, creating a portfolio for treating a wide variety of pathologies in various surgical approaches.

- **Product Profile/Pipeline**
  Carevature's Dreal® line of freehand devices is further developed to provide real-time visualization and tip articulation, which will greatly enhance its use. In parallel, a first-generation, single-arm robotic platform is developed to be the first in the market with spinal decompression capabilities. A second-generation, multiple-arms platform will follow, allowing end-to-end robotic procedures for a wider range of spinal conditions.

- **What's Next?**
  Carevature completed a Proof-of-Concept program, in which 10 US and Israeli surgeons performed 4 live animal and 2 human cadaver trials, demonstrating the viability of the vision-guided, surgeon-controlled concept in performing a safe and efficient spinal decompression. Work on the next milestones, planned for Q1-2023 (First in Human cases) and Q3-2023 (FDA submission), is already in high gear.